Biotechnological advances target metabolic and cardiovascular disorders. Phase II siRNA candidate zerlasiran demonstrated promising lipoprotein(a) lowering effects, potentially addressing a prevalent inherited risk factor for atherosclerotic cardiovascular disease, per cardiologist-led trials. Companies like Structure Therapeutics and Mira Pharmaceuticals presented new dual receptor agonists and drug candidates aiming at obesity and related addictions. Novartis inked a multi-million-dollar deal with ProFound Therapeutics to discover novel cardiovascular drug targets using proteomics. Regulatory bodies continue to update guidelines reflecting emergent therapies addressing complex cardiometabolic conditions.